Pfizer completes its next milestone in the battle against the pandemic

Pfizer Inc (NYSE: PFE) said on Monday its COVID-19 vaccine developed in collaboration with Germany’s BioNTech is just as effective in children (5- to-11-year-olds) as it was in adults. The Phase II and III clinical trials also established the vaccine as generally safe for children. The U.S. pharmaceutical giant now plans on requesting authorisation from […]